Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 682 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: i-scan Clear all
Recruiting Not applicable Interventional

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT06682442
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer, Nasopharyngeal Cancer Stage
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
Radiation · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Single Session Stereotactic Body Radiotherapy

NCT00492817
View directory record Official record
Conditions
Spinal Neoplasms
Interventions
Stereotactic Body Radiotherapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NCT05095376
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
418
States / cities
Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

NCT04086485
View directory record Official record
Conditions
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

NCT03927885
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Waiting List
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

NCT05863351
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, Systemic Therapy
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
108
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

NCT07213154
View directory record Official record
Conditions
Malignant Skin Neoplasm, Skin Disorder, Skin Neoplasm
Interventions
Quantitative Oblique Back-Illumination Microscopy, Radiation Therapy
Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study

NCT05455086
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Cigarette Smoking, Computed Tomography, Positron Emission Tomography, Questionnaire Administration
Behavioral · Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

NCT03907488
View directory record Official record
Conditions
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
711
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Not applicable Interventional

Early Detection Initiative for Pancreatic Cancer

NCT04662879
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus, Pancreas Ductal Adenocarcinoma
Interventions
Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score, Abdominal imaging
Other
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
50 Years to 85 Years
Enrollment
8,869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Pasadena, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06871410
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Hydroxyurea, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410
View directory record Official record
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
404
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

NCT02961491
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane I131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
3
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Intervening on Women's Health for Rural Young Cancer Survivors

NCT06664034
View directory record Official record
Conditions
Cancer, Fertility Issues, Contraception
Interventions
Multi-component reproductive health care intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
15 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Brawley, California • El Centro, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Phase 2 Interventional

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
453
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed No phase listed Observational

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

NCT01664936
View directory record Official record
Conditions
Head and Neck Cancers
Interventions
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

NCT05805371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Lymphodepletion Therapy
Biological · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
275
States / cities
Birmingham, Alabama • Clovis, California • Concord, California + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

I-scan for Adenoma Detection

NCT02811419
View directory record Official record
Conditions
Colorectal Adenomatous Polyps
Interventions
i-scan, standard high-definition white light
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 75 Years
Enrollment
740 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 30, 2026, 4:27 PM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02912559
View directory record Official record
Conditions
Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1026
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting No phase listed Observational

Investigating the Impact of Proactive Palliative Care

NCT03667378
View directory record Official record
Conditions
Metastatic Solid Tumor Cancers, Locally Advanced Solid Tumor Cancers
Interventions
Expectations Survey (CanCORS), Values Survey (Serious Illness Care Program), Functional Assessment of Cancer Therapy-General (FACT-G), NCCN Distress Thermometer, Hospital Anxiety and Depression Scale (HADS), Quality of Communication (QOC), visits with a supportive care clinician
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Not applicable Interventional

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

NCT03234556
View directory record Official record
Conditions
Health Status Unknown, Elevated PSA
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy
Procedure · Other · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 4:27 PM EDT